In the news this week: J&J settlements and talc litigation. Erik Haas’s current role anchors the story; a concise biographical line gives context without speculation.
Johnson & Johnson has reached a landmark settlement to resolve about 76,000 talc-related claims alleging ovarian cancer, potentially ending a decade-long legal battle. The deal requires 95% court acceptance and could total well above $3 billion, with payments beginning in 2027 and continuing into 2028; total payout could rise to $7 billion or more depending on participation.